Cardiothoracic & vascular anesthesia
Continuous Glucose Monitoring and the Effect of Liraglutide in Cardiac Surgery Patients: A Substudy of the Randomized Controlled GLOBE Trial
Primary result · Glycemic time in rangeResult — go to the resultAbsolute difference 25% 95% CI −41.4 to −8.9Authors' conclusion
Despite intraoperative sensor interruption, CGM seems an accurate method for semi-invasive, real-time assessment of blood glucose levels. CGM can provide a detailed observation of the pre- and postoperative glycemic trajectory, demonstrating increased time in range following perioperative liraglutide treatment compared with placebo.
Study context
- Population
- Patients undergoing cardiac surgery, single-centre academic hospital in the Netherlands
- Participants
- 25 patients
- Comparison
- Liraglutide vs Placebo
- Primary endpoint
- Accuracy and reliability of CGM (Dexcom G5) vs ABG glucose; effect of preoperative liraglutide on perioperative glucose control by CGM
Methodological detailsprospective, single-centre, prespecified analysis
- Prospective
- Single-centre
- Prespecified analysis
Primary result
Glycemic time in range
Absolute difference
25%
95% CI −41.4 to −8.9
P = 0.004
By group
As reported in the abstract
- Continuous glucose monitoring (CGM) vs arterial blood gas (ABG) mean absolute relative difference (240 paired measurements)
- 14.4 ± 12.5%
Further findings
CGM sensor interruption · intraoperative
- Temporary sensor interruption, mainly intraoperative (% of patients)
- 92%
- Median duration of intraoperative sensor interruption, minutes
- 65 (48-95)
Original publication
Continuous Glucose Monitoring and the Effect of Liraglutide in Cardiac Surgery Patients: A Substudy of the Randomized Controlled GLOBE Trial. J Cardiothorac Vasc Anesth. Published 18 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →